Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

NewAmsterdam Pharma (NAMSW) EBT Margin (2023 - 2025)

Historic EBT Margin for NewAmsterdam Pharma (NAMSW) over the last 3 years, with Q3 2025 value amounting to 20691.09%.

  • NewAmsterdam Pharma's EBT Margin fell 206339000.0% to 20691.09% in Q3 2025 from the same period last year, while for Sep 2025 it was 627.28%, marking a year-over-year decrease of 352400.0%. This contributed to the annual value of 530.25% for FY2024, which is 7253200.0% up from last year.
  • Per NewAmsterdam Pharma's latest filing, its EBT Margin stood at 20691.09% for Q3 2025, which was down 206339000.0% from 90.7% recorded in Q2 2025.
  • NewAmsterdam Pharma's 5-year EBT Margin high stood at 57.19% for Q3 2024, and its period low was 20691.09% during Q3 2025.
  • Over the past 3 years, NewAmsterdam Pharma's median EBT Margin value was 1602.62% (recorded in 2023), while the average stood at 3797.5%.
  • As far as peak fluctuations go, NewAmsterdam Pharma's EBT Margin soared by 54386900bps in 2024, and later tumbled by -206339000bps in 2025.
  • NewAmsterdam Pharma's EBT Margin (Quarter) stood at 6160.4% in 2023, then surged by 88bps to 721.71% in 2024, then plummeted by -2767bps to 20691.09% in 2025.
  • Its EBT Margin was 20691.09% in Q3 2025, compared to 90.7% in Q2 2025 and 1327.3% in Q1 2025.